$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx

$rxrx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000160183024000019 Filed on February 29, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$10.89M	$44.58M	$13.68M
YoY Change	-20.36%	11.88%	439.91%
Cost Of Revenue	$9.881M	$42.59M	$10.84M
YoY Change	-8.85%	-11.78%
Gross Profit	$1.010M	$1.988M	$2.836M
YoY Change	-64.39%	-123.58%
Gross Profit Margin	9.27%	4.46%	20.74%
Selling, General & Admin	$36.96M	$134.0M	$23.36M
YoY Change	58.24%	40.07%	9.04%
% of Gross Profit	3659.21%	6739.59%	823.55%
Research & Development	$59.58M	$241.2M	$40.31M
YoY Change	47.81%	54.93%	-12.36%
% of Gross Profit	5899.21%	12134.1%	1421.4%
Depreciation & Amortization	$7.553M	$24.40M	$3.214M
YoY Change	135.0%	107.57%	43.74%
% of Gross Profit	747.82%	1227.46%	113.33%
Operating Expenses	$99.94M	$241.2M	$63.82M
YoY Change	56.6%	54.93%	-5.45%
Operating Profit	-$98.93M	-$350.1M	-$60.98M
YoY Change	62.23%	42.46%
Interest Expense	$4.496M	$97.00K	$3.669M
YoY Change	22.54%	76.36%	-183550.0%
% of Operating Profit
Other Income/Expense, Net	-$2.624M	$17.93M	-$179.0K
YoY Change	1365.92%	186.87%	-717.24%
Pretax Income	-$97.06M	-$332.1M	-$57.49M
YoY Change	68.82%	38.69%	-11.46%
Income Tax	-$4.062M	-$4.062M
% Of Pretax Income
Net Earnings	-$93.00M	-$328.1M	-$57.49M
YoY Change	61.75%	36.99%	-11.46%
Net Earnings / Revenue	-853.88%	-735.99%	-420.39%
Basic Earnings Per Share		-$1.58
Diluted Earnings Per Share	-$0.40	-$1.58	-$0.31
COMMON SHARES
Basic Shares Outstanding		207.9M shares
Diluted Shares Outstanding		207.9M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$391.6M	$391.6M	$549.9M
YoY Change	-28.79%	-28.79%	6.46%
Cash & Equivalents	$391.6M	$391.6M	$549.9M
Short-Term Investments			$0.00
Other Short-Term Assets	$40.25M	$43.48M	$15.87M
YoY Change	153.62%	153.53%	111.19%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables	$3.094M		$2.753M
Total Short-Term Assets	$438.1M	$438.1M	$569.8M
YoY Change	-23.11%	-23.11%	6.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.51M	$120.2M	$88.19M
YoY Change	-1.91%	-1.05%	36.26%
Goodwill	$52.06M		$801.0K
YoY Change	6398.88%		0.0%
Intangibles	$36.44M		$1.306M
YoY Change	2690.43%		-5.7%
Long-Term Investments
YoY Change
Other Assets	$261.0K	$6.890M	$0.00
YoY Change		-13.01%	-100.0%
Total Long-Term Assets	$215.6M	$215.6M	$131.5M
YoY Change	63.96%	63.96%	73.85%
TOTAL ASSETS
Total Short-Term Assets	$438.1M	$438.1M	$569.8M
Total Long-Term Assets	$215.6M	$215.6M	$131.5M
Total Assets	$653.7M	$653.7M	$701.3M
YoY Change	-6.79%	-6.79%	14.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.953M	$3.953M	$4.586M
YoY Change	-13.8%	-13.8%	62.68%
Accrued Expenses	$46.64M	$52.75M	$32.90M
YoY Change	41.73%	35.76%	1.77%
Deferred Revenue	$36.43M		$56.73M
YoY Change	-35.79%		467.26%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$41.00K	$41.00K	$97.00K
YoY Change	-57.73%	-57.73%	7.78%
Total Short-Term Liabilities	$93.17M	$93.17M	$100.3M
YoY Change	-7.08%	-7.08%	114.89%
LONG-TERM LIABILITIES
Long-Term Debt	$1.101M	$1.101M	$536.0K
YoY Change	105.41%	105.41%	-15.32%
Other Long-Term Liabilities	$94.65M	$94.65M	$114.7M
YoY Change	-17.46%	-17.46%	470.1%
Total Long-Term Liabilities	$95.75M	$95.75M	$115.2M
YoY Change	-16.89%	-16.89%	455.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.17M	$93.17M	$100.3M
Total Long-Term Liabilities	$95.75M	$95.75M	$115.2M
Total Liabilities	$190.3M	$190.3M	$215.5M
YoY Change	-11.7%	-11.7%	219.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$967.6M		-$639.6M
YoY Change	51.28%		59.87%
Common Stock	$2.000K		$2.000K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$463.4M	$463.4M	$485.8M
YoY Change
Total Liabilities & Shareholders Equity	$653.7M	$653.7M	$701.3M
YoY Change	-6.79%	-6.79%	14.9%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$93.00M	-$328.1M	-$57.49M
YoY Change	61.75%	36.99%	-11.46%
Depreciation, Depletion And Amortization	$7.553M	$24.40M	$3.214M
YoY Change	135.0%	107.57%	43.74%
Cash From Operating Activities	-$74.08M	-$287.8M	-$44.75M
YoY Change	65.54%	244.55%	-26.83%
INVESTING ACTIVITIES
Capital Expenditures	$2.067M	$11.96M	$7.979M
YoY Change	-74.09%	-67.74%	-278.74%
Acquisitions		-$1.844M
YoY Change
Other Investing Activities	-$421.0K	$1.727M	$0.00
YoY Change		-99.25%	-100.0%
Cash From Investing Activities	-$2.488M	-$10.23M	-$7.979M
YoY Change	-68.82%	-105.29%	-84.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$128.1M
YoY Change		-10.87%
Debt Paid & Issued, Net		$766.0K
YoY Change		751.11%
Cash From Financing Activities	80.66M	$140.1M	147.3M
YoY Change	-45.23%	-9.21%	3779.24%
NET CHANGE
Cash From Operating Activities	-74.08M	-$287.8M	-44.75M
Cash From Investing Activities	-2.488M	-$10.23M	-7.979M
Cash From Financing Activities	80.66M	$140.1M	147.3M
Net Change In Cash	4.094M	-$157.7M	94.53M
YoY Change	-95.67%	-159.78%	-186.25%
FREE CASH FLOW
Cash From Operating Activities	-$74.08M	-$287.8M	-$44.75M
Capital Expenditures	$2.067M	$11.96M	$7.979M
Free Cash Flow	-$76.14M	-$299.7M	-$52.73M
YoY Change	44.41%	148.57%	-7.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	394635000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	285570000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-350060000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-245727000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-182775000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207853702	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125348110	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125348110	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-162000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10228000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207853702	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	175537487	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-239476000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8437000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	766000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	90000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001601830
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40323
CY2023	dei	Entity Registrant Name EntityRegistrantName	Recursion Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4099738
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	41 S Rio Grande Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84101
CY2023	dei	City Area Code CityAreaCode	385
CY2023	dei	Local Phone Number LocalPhoneNumber	269 - 0203
CY2023	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.00001
CY2023	dei	Trading Symbol TradingSymbol	RXRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	930400000	usd
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391565000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	549912000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3231000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1280000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3094000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2753000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	40247000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15869000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	438137000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	569814000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6629000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	7920000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	86510000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88192000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33663000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33255000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	36443000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1306000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	52056000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	801000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	261000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Assets Assets	653699000	usd
CY2022Q4	us-gaap	Assets Assets	701288000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3953000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4586000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46635000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32904000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	36426000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	56726000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	41000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	97000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6116000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5952000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93171000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	100265000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	51238000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	70261000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1101000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	536000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43414000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44420000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1339000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	190263000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	215482000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	191022864	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	191022864	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1431056000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1125360000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-967622000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-639556000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	463436000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	485806000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	653699000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	701288000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10178000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	110822000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17932000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6251000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3704000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-332128000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-239476000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-186479000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4062000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-328066000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-239476000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175537487	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-328066000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	87000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-39000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-36000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	126000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-328066000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-239350000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-186605000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	112088065	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	448312000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-206289000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-186605000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462354000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	448312000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6812000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14842000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542938000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-239350000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	143711000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10598000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27909000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	485806000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-328066000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12831000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	53503000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	128093000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	89269000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	463436000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-328066000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-239476000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24402000	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7730000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-827000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3387000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-830000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4097000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7756000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5376000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-41076000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	110320000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-987000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1767000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1745000	usd
CY2023	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	2705000	usd
CY2022	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	522000	usd
CY2021	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	561000	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	6719000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-576000	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	12764000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9862000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7110000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-287780000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83524000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-158614000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-1844000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11955000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37059000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39798000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	597000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	300000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	301137000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	480000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	230608000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	69191000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	193249000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-271744000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128093000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	143711000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	462901000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12806000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10724000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12798000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140133000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154345000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	458540000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-307000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-157687000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	263763000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28182000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	559112000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295349000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267167000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401425000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	559112000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295349000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	89269000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4968000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3950000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2439000	usd
CY2023	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	0	usd
CY2022	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	0	usd
CY2021	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	547000	usd
CY2023	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	9862000	usd
CY2022	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	7110000	usd
CY2021	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	96000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	591000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7749000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	448312000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	55000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	680000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, the Company converted to a Delaware corporation and changed its name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery. The Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe, one of the world’s largest proprietary biological and chemical datasets. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hypotheses into validated insights and novel chemistry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, the Company had an accumulated deficit of $967.6 million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations to date primarily through the issuance of convertible preferred stock and the issuance of Class A common stock (see Note 8, “Common Stock” for additional details). Additionally, the Company has received payments from its strategic partnerships (see Note 9, “Collaborative Development Contracts” for additional details). Recursion will likely be required to raise additional capital. As of December 31, 2023, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion believes that the Company’s existing cash and cash equivalents will be sufficient to fund the Company’s operating expenses and capital expenditures for at least the next 12 months.</span></div>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-967600000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires the Company to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those amounts. Significant estimates and assumptions include the estimated progress towards the satisfaction of performance obligations to record revenue, the valuation of goodwill and intangible assets, accrued research and development expenses and the fair value of stock-based awards issued.</span></div>
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.5
CY2021Q2	rxrx	Number Of Classes Of Common Stock Authorized NumberOfClassesOfCommonStockAuthorized	2	class
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. These financial instruments are primarily held at two U.S. financial institutions that management believes are of high credit quality. Recursion’s primary bank accounts significantly exceed the federally insured limits. </span></div>The Company is dependent on third-party suppliers for certain research and development activities including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers. These activities could be adversely affected by a significant interruption to Recursion’s third-party suppliers including a delay in the Company’s preclinical and clinical testing and the supply of certain consumable products and compounds.
CY2023Q4	rxrx	Number Of Financial Institutions Where Financial Instruments Are Primarily Held NumberOfFinancialInstitutionsWhereFinancialInstrumentsArePrimarilyHeld	2	financial_institution
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32900000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	47800000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	131382000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	118307000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	44872000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30115000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	86510000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88192000	usd
CY2023	us-gaap	Depreciation Depreciation	15900000	usd
CY2022	us-gaap	Depreciation Depreciation	11400000	usd
CY2021	us-gaap	Depreciation Depreciation	8800000	usd
CY2023	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1200000	usd
CY2022	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	2800000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10399000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10526000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10769000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7397000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17014000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	66164000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16634000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	49530000	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6400000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22888000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20433000	usd
CY2023Q4	rxrx	Accrued Development Costs Current AccruedDevelopmentCostsCurrent	6077000	usd
CY2022Q4	rxrx	Accrued Development Costs Current AccruedDevelopmentCostsCurrent	3372000	usd
CY2023Q4	rxrx	Accrued Early Discovery Expenses Current AccruedEarlyDiscoveryExpensesCurrent	2570000	usd
CY2022Q4	rxrx	Accrued Early Discovery Expenses Current AccruedEarlyDiscoveryExpensesCurrent	3192000	usd
CY2023Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	2439000	usd
CY2022Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	591000	usd
CY2023Q4	rxrx	Materials Received Not Invoiced MaterialsReceivedNotInvoiced	2432000	usd
CY2022Q4	rxrx	Materials Received Not Invoiced MaterialsReceivedNotInvoiced	2028000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10229000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3288000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46635000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32904000	usd
CY2023	us-gaap	Interest Expense InterestExpense	97000	usd
CY2022	us-gaap	Interest Expense InterestExpense	55000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2952000	usd
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	19116000	usd
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	6254000	usd
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	73000	usd
CY2023	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	19019000	usd
CY2022	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	6199000	usd
CY2021	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-2879000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	801000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	51255000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	52056000	usd
CY2023	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023	rxrx	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	3400000	usd
CY2022	rxrx	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-2700000	usd
CY2022	rxrx	Lessee Operating Lease Increase Decrease In Operating Lease Liability Due To Lease Modifications LesseeOperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilityDueToLeaseModifications	-2800000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	8144000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	7793000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	2116000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1070000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	139000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	10399000	usd
CY2022	us-gaap	Lease Cost LeaseCost	8863000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.073
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10059000	usd
CY2022	us-gaap	Dividends Stock DividendsStock	0	usd
CY2022Q4	rxrx	Percent Of Aggregate Purchase Price Paid By The Holder Due If Agreement Is Broken PercentOfAggregatePurchasePricePaidByTheHolderDueIfAgreementIsBroken	0.01
CY2023Q4	rxrx	Registration Rights Agreement Accrued Liability RegistrationRightsAgreementAccruedLiability	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	44426000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8969000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	35457000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1211000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	809000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	402000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	986000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	904000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	379000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	304000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P2Y9M18D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13379000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13116000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7672000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1283000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	4	claim
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q2	rxrx	Number Of Classes Of Common Stock Authorized NumberOfClassesOfCommonStockAuthorized	2	class
CY2023Q4	rxrx	Common Stock Conversion Ratio CommonStockConversionRatio	1
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51679000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26872000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13830000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16154924	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.10
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	67997000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5083268	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.23
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1460517	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.67
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4820058	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	32621000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14957617	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.13
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	72416000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9844841	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.07
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	59144000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.64
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.57
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.66
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	32600000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.04
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3800000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-82707000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-61225000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-47138000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-54634000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3188000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	684000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4564000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-471000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-149000	usd
CY2023	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	137843000	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	64884000	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	46603000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4062000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.031
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.037
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.032
CY2023	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.021
CY2022	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.011
CY2021	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.164
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.006
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.415
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.255
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.012
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	117877000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	89951000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	105503000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	39095000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	50293000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	30965000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	23007000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	usd
CY2023Q4	rxrx	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	13208000	usd
CY2022Q4	rxrx	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	11442000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4744000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3622000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5080000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2231000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	969000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	485000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	433000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	320197000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	178708000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	304618000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	166775000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15579000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11933000	usd
CY2023Q4	rxrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	8942000	usd
CY2022Q4	rxrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	9982000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	5272000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2704000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1951000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16918000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11933000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1339000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	304600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	166800000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	137800000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	64700000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2762000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1944000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1726000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	818000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	929000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5417000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2762000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-328066000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-239476000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207853702	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207853702	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175537487	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	175537487	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125348110	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125348110	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10921975	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10966651	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50148845	shares
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001601830-24-000019-index-headers.html	Edgar Link	pending
0001601830-24-000019-index.html	Edgar Link	pending
0001601830-24-000019.txt	Edgar Link	pending
0001601830-24-000019-xbrl.zip	Edgar Link	pending
exhibit1021-rxrxxbayeragre.htm	Edgar Link	pending
exhibit211-10xk2023.htm	Edgar Link	pending
exhibit231-eyconsent.htm	Edgar Link	pending
exhibit311-10xk23.htm	Edgar Link	pending
exhibit312-10xk23.htm	Edgar Link	pending
exhibit321-10xk23.htm	Edgar Link	pending
exhibit42-descriptionofsec.htm	Edgar Link	pending
exhibit971-clawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxrx-20231231.htm	Edgar Link	pending
rxrx-20231231.xsd	Edgar Link	pending
rxrx-20231231_g1.jpg	Edgar Link	pending
rxrx-20231231_g10.jpg	Edgar Link	pending
rxrx-20231231_g11.jpg	Edgar Link	pending
rxrx-20231231_g12.jpg	Edgar Link	pending
rxrx-20231231_g13.jpg	Edgar Link	pending
rxrx-20231231_g14.jpg	Edgar Link	pending
rxrx-20231231_g15.jpg	Edgar Link	pending
rxrx-20231231_g16.jpg	Edgar Link	pending
rxrx-20231231_g17.jpg	Edgar Link	pending
rxrx-20231231_g18.jpg	Edgar Link	pending
rxrx-20231231_g19.jpg	Edgar Link	pending
rxrx-20231231_g2.jpg	Edgar Link	pending
rxrx-20231231_g20.jpg	Edgar Link	pending
rxrx-20231231_g21.jpg	Edgar Link	pending
rxrx-20231231_g22.jpg	Edgar Link	pending
rxrx-20231231_g23.jpg	Edgar Link	pending
rxrx-20231231_g24.jpg	Edgar Link	pending
rxrx-20231231_g25.jpg	Edgar Link	pending
rxrx-20231231_g26.jpg	Edgar Link	pending
rxrx-20231231_g27.jpg	Edgar Link	pending
rxrx-20231231_g28.jpg	Edgar Link	pending
rxrx-20231231_g29.jpg	Edgar Link	pending
rxrx-20231231_g3.jpg	Edgar Link	pending
rxrx-20231231_g30.jpg	Edgar Link	pending
rxrx-20231231_g31.jpg	Edgar Link	pending
rxrx-20231231_g32.jpg	Edgar Link	pending
rxrx-20231231_g33.jpg	Edgar Link	pending
rxrx-20231231_g34.jpg	Edgar Link	pending
rxrx-20231231_g35.jpg	Edgar Link	pending
rxrx-20231231_g36.jpg	Edgar Link	pending
rxrx-20231231_g37.jpg	Edgar Link	pending
rxrx-20231231_g38.jpg	Edgar Link	pending
rxrx-20231231_g39.jpg	Edgar Link	pending
rxrx-20231231_g4.jpg	Edgar Link	pending
rxrx-20231231_g40.jpg	Edgar Link	pending
rxrx-20231231_g41.jpg	Edgar Link	pending
rxrx-20231231_g42.jpg	Edgar Link	pending
rxrx-20231231_g43.jpg	Edgar Link	pending
rxrx-20231231_g44.jpg	Edgar Link	pending
rxrx-20231231_g45.jpg	Edgar Link	pending
rxrx-20231231_g46.jpg	Edgar Link	pending
rxrx-20231231_g47.jpg	Edgar Link	pending
rxrx-20231231_g48.jpg	Edgar Link	pending
rxrx-20231231_g49.jpg	Edgar Link	pending
rxrx-20231231_g5.jpg	Edgar Link	pending
rxrx-20231231_g50.jpg	Edgar Link	pending
rxrx-20231231_g51.jpg	Edgar Link	pending
rxrx-20231231_g52.jpg	Edgar Link	pending
rxrx-20231231_g53.jpg	Edgar Link	pending
rxrx-20231231_g54.jpg	Edgar Link	pending
rxrx-20231231_g55.jpg	Edgar Link	pending
rxrx-20231231_g56.jpg	Edgar Link	pending
rxrx-20231231_g57.jpg	Edgar Link	pending
rxrx-20231231_g58.jpg	Edgar Link	pending
rxrx-20231231_g59.jpg	Edgar Link	pending
rxrx-20231231_g6.jpg	Edgar Link	pending
rxrx-20231231_g60.jpg	Edgar Link	pending
rxrx-20231231_g61.jpg	Edgar Link	pending
rxrx-20231231_g62.jpg	Edgar Link	pending
rxrx-20231231_g63.jpg	Edgar Link	pending
rxrx-20231231_g64.jpg	Edgar Link	pending
rxrx-20231231_g65.jpg	Edgar Link	pending
rxrx-20231231_g66.jpg	Edgar Link	pending
rxrx-20231231_g67.jpg	Edgar Link	pending
rxrx-20231231_g68.jpg	Edgar Link	pending
rxrx-20231231_g69.jpg	Edgar Link	pending
rxrx-20231231_g7.jpg	Edgar Link	pending
rxrx-20231231_g70.jpg	Edgar Link	pending
rxrx-20231231_g71.jpg	Edgar Link	pending
rxrx-20231231_g72.jpg	Edgar Link	pending
rxrx-20231231_g73.jpg	Edgar Link	pending
rxrx-20231231_g74.jpg	Edgar Link	pending
rxrx-20231231_g75.jpg	Edgar Link	pending
rxrx-20231231_g76.jpg	Edgar Link	pending
rxrx-20231231_g77.jpg	Edgar Link	pending
rxrx-20231231_g78.jpg	Edgar Link	pending
rxrx-20231231_g79.jpg	Edgar Link	pending
rxrx-20231231_g8.jpg	Edgar Link	pending
rxrx-20231231_g80.jpg	Edgar Link	pending
rxrx-20231231_g81.jpg	Edgar Link	pending
rxrx-20231231_g9.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
rxrx-20231231_lab.xml	Edgar Link	unprocessable
rxrx-20231231_pre.xml	Edgar Link	unprocessable
rxrx-20231231_htm.xml	Edgar Link	completed
rxrx-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
rxrx-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx

2023 Q4 Form 10-K Financial Statement

#000160183024000019 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXRX RECURSION PHARMACEUTICALS, INC. Stock $rxrx

2023 Q4 Form 10-K Financial Statement

#000160183024000019 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx